Toward aggregation-resistant antibodies by design
CC Lee, JM Perchiacca, PM Tessier - Trends in biotechnology, 2013 - cell.com
Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …
disorders due to their exquisite binding specificity and high binding affinity. However, a …
Toward aggregation-resistant antibodies by design
CC Lee, JM Perchiacca… - Trends in …, 2013 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …
disorders due to their exquisite binding specificity and high binding affinity. However, a …
Toward aggregation-resistant antibodies by design
CC Lee, JM Perchiacca, PM Tessier - Trends in Biotechnology, 2013 - infona.pl
Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …
disorders due to their exquisite binding specificity and high binding affinity. However, a …
[引用][C] Toward aggregation-resistant antibodies by design
CC LEE, JM PERCHIACCA… - Trends in biotechnology …, 2013 - pascal-francis.inist.fr
Toward aggregation-resistant antibodies by design CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Toward aggregation-resistant antibodies by design
CC Lee, JM Perchiacca, PM Tessier - Trends in Biotechnology, 2013 - Elsevier
Highlights•Therapeutic antibodies possess highly variable propensities to
aggregate.•Antibody CDRs, frameworks, and domain interfaces strongly influence solubility.• …
aggregate.•Antibody CDRs, frameworks, and domain interfaces strongly influence solubility.• …
Toward aggregation-resistant antibodies by design.
CC Lee, JM Perchiacca, PM Tessier - Trends in Biotechnology, 2013 - europepmc.org
Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …
disorders due to their exquisite binding specificity and high binding affinity. However, a …